One increasingly popular therapy for treating prostate cancer is testosterone replacement therapy, or TRT. It has become quite common during the last 10 years. Until recently, testosterone hormone treatments were only given in situations in which a patient has a rare medical condition like hypogonadism.
Although the majority of men who take testosterone replacement therapy routinely do not have hypogonadism, they can access the drug as the result of a loophole in the FDA’s regulations governing TRT. This loophole authorizes physicians to prescribe certain drugs for uses that are not included on the label. So far, the FDA has only authorized TRT for men experiencing low levels of testosterone due to medical conditions limiting production of testosterone in the testicles.
Referred to as off-label uses, there has been a recent surge in the number of instances in which doctors are being fined and disciplined for permitting Low T clinics to give testosterone prescriptions to patients without ever actually meeting or examining the patient.